AI-Driven Digital Twins for Precision Oncology King’s College London in United Kingdom

Join the Sailem group at the School of Cancer and Pharmaceutical Sciences, King’s College London, for a PhD project at the forefront of computational pathology and precision oncology. This opportunity allows you to contribute to the development of digital tumour twins—advanced computational models that leverage predictive analytics and deep learning to improve cancer diagnosis and treatment. The project integrates patient medical history, personal characteristics, and detailed tumour features extracted from histopathology images, aiming to create age- and gender-matched tumour twins for personalized medicine.

As a PhD student, you will design and develop digital models of tumour behaviours, integrate component models into unified digital twins, and validate these models using experimental data. The research is highly collaborative, involving close work with clinicians to ensure clinical relevance and impact, including the development of visualization methods tailored for clinical use.

The Sailem group is a dynamic, multidisciplinary team working at the intersection of AI, computational pathology, and oncology. You will gain expertise in digital twins, computer vision, deep learning, biomedical data analysis, and interdisciplinary research. The project is ideal for graduates with backgrounds in Computer Science, Artificial Intelligence, Biomedical Engineering, Computer Vision, Bioinformatics, or Mathematics. Candidates interested in lab-based projects are also encouraged to apply.

Applicants must possess a first or upper-second-class degree in a relevant scientific field. Funding is available for students eligible for the China Scholarship Council (CSC) or those with independent funding. Applications are accepted year-round. For further information, visit the group website or explore related resources:

• Sailem Group Website
• HistopathExpo
• TissuePlot Project

To apply, email your CV and personal statement to Dr Heba Sailem at [email protected], including details of your funding eligibility.